Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Ipamorelin vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Ipamorelin (Anecdotal + Phase 2) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Ipamorelin

Anecdotal + Phase 2

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Ipamorelin Tesamorelin + Ipamorelin
Class Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route SC injection SC injection
Half-life ~2 hrs Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier Anecdotal + Phase 2 FDA-Approved (component)
Research depth 64 indexed (PubMed 42 · CT 3 · EPMC 19) —
Availability Compounding Restricted Compounding Restricted
Reported risks Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Ipamorelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than Ipamorelin (Anecdotal + Phase 2) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Ipamorelin and Tesamorelin + Ipamorelin?

Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Ipamorelin, ~2 hrs; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Ipamorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, Ipamorelin or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.

Which is more accessible, Ipamorelin or Tesamorelin + Ipamorelin?

Neither Ipamorelin nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; Tesamorelin + Ipamorelin, Compounding Restricted. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Ipamorelin and Tesamorelin + Ipamorelin ever combined?

Ipamorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…